PURVI Devchand GADA
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- Chaska, MN
- NPI
- 1639209224
- Received
- $75,754 in 75 records, 2019 to 2025
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 19 | $20,917 |
| 2024 | General payment | 21 | $15,846 |
| 2023 | General payment | 8 | $10,551 |
| 2022 | General payment | 9 | $11,413 |
| 2021 | General payment | 5 | $7,269 |
| 2020 | General payment | 4 | $3,478 |
| 2019 | General payment | 9 | $6,277 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 38 | $49,045 | 2021–2025 |
| Gilead Sciences, Inc. | 9 | $6,688 | 2021–2024 |
| Rigel Pharmaceuticals, Inc. | 7 | $4,122 | 2019 |
| Daiichi Sankyo Inc. | 3 | $2,786 | 2020–2022 |
| GlaxoSmithKline, LLC. | 1 | $2,750 | 2021 |
| Janssen Biotech, Inc. | 2 | $2,250 | 2021–2023 |
| GENZYME CORPORATION | 2 | $2,155 | 2019 |
| BeiGene USA, Inc. | 1 | $1,925 | 2024 |
| Deciphera Pharmaceuticals Inc. | 5 | $1,448 | 2025 |
| Immunomedics, Inc. | 1 | $1,225 | 2020 |
| Aadi Bioscience, Inc. | 1 | $1,000 | 2023 |
| Intera Oncology, Inc | 1 | $186 | 2024 |
| Allergan, Inc. | 1 | $120 | 2022 |
| E.R. Squibb & Sons, L.L.C. | 3 | $49 | 2020–2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 20 | $40,681 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 18 | $28,745 |
| Honoraria | 3 | $2,825 |
| Food and Beverage | 22 | $1,719 |
| Travel and Lodging | 8 | $1,616 |
| Grant | 1 | $120 |
| Education | 3 | $47 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | AstraZeneca Pharmaceuticals LP | $2,010 | Consulting Fee | Cash or cash equivalent | Truqap Drug, Oncology | 2025 | |
| 2025-12-05 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-12-05 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-11-14 | AstraZeneca Pharmaceuticals LP | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $110 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-22 | AstraZeneca Pharmaceuticals LP | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-18 | AstraZeneca Pharmaceuticals LP | $108 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-19 | AstraZeneca Pharmaceuticals LP | $2,680 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-22 | AstraZeneca Pharmaceuticals LP | $1,675 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-20 | AstraZeneca Pharmaceuticals LP | $1,675 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2025 | |
| 2025-05-01 | Deciphera Pharmaceuticals Inc. | $1,275 | Honoraria | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-05-01 | Deciphera Pharmaceuticals Inc. | $64 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-05-01 | Deciphera Pharmaceuticals Inc. | $62 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-05-01 | Deciphera Pharmaceuticals Inc. | $26 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-05-01 | Deciphera Pharmaceuticals Inc. | $20 | Travel and Lodging | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-03-10 | AstraZeneca Pharmaceuticals LP | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-03-06 | AstraZeneca Pharmaceuticals LP | $99 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-05 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-01-16 | AstraZeneca Pharmaceuticals LP | $2,220 | Consulting Fee | Cash or cash equivalent | IMJUDO Biological, Oncology | 2025 | |
| 2024-12-12 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-12-10 | AstraZeneca Pharmaceuticals LP | $2,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-12-05 | AstraZeneca Pharmaceuticals LP | $93 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-23 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-10-17 | Gilead Sciences, Inc. | $2,860 | Consulting Fee | Cash or cash equivalent | Trodelvy Drug, ONC | 2024 | |
| 2024-10-12 | Gilead Sciences, Inc. | $59 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2024 | |
| 2024-10-12 | Gilead Sciences, Inc. | $56 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2024 | |
| 2024-10-12 | Gilead Sciences, Inc. | $56 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2024 | |
| 2024-10-11 | Gilead Sciences, Inc. | $423 | Travel and Lodging | In-kind items and services | Trodelvy Drug, ONC | 2024 | |
| 2024-10-11 | Gilead Sciences, Inc. | $303 | Travel and Lodging | In-kind items and services | Trodelvy Drug, ONC | 2024 | |
| 2024-10-11 | Gilead Sciences, Inc. | $115 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2024 | |
| 2024-09-06 | AstraZeneca Pharmaceuticals LP | $2,220 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-08-28 | AstraZeneca Pharmaceuticals LP | $1,387 | Consulting Fee | Cash or cash equivalent | ENHERTU Biological, Oncology | 2024 | |
| 2024-06-06 | Intera Oncology, Inc | $186 | Food and Beverage | In-kind items and services | INTERA Device, ONCOLOGY | 2024 | |
| 2024-05-24 | BeiGene USA, Inc. | $1,925 | Consulting Fee | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2024 | |
| 2024-05-17 | AstraZeneca Pharmaceuticals LP | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-05-15 | AstraZeneca Pharmaceuticals LP | $127 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-05-15 | AstraZeneca Pharmaceuticals LP | $33 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2024 | |
| 2024-01-29 | E.R. Squibb & Sons, L.L.C. | $16 | Education | In-kind items and services | REBLOZYL Biological, Hematology | 2024 | |
| 2024-01-04 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2024-01-04 | AstraZeneca Pharmaceuticals LP | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2024 | |
| 2023-11-01 | AstraZeneca Pharmaceuticals LP | $1,387 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-10-02 | Aadi Bioscience, Inc. | $1,000 | Honoraria | Cash or cash equivalent | Fyarro Drug, Cancer | 2023 | |
| 2023-09-29 | AstraZeneca Pharmaceuticals LP | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-09-26 | AstraZeneca Pharmaceuticals LP | $135 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2023 | |
| 2023-06-14 | Janssen Biotech, Inc. | $1,350 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-05-29 | AstraZeneca Pharmaceuticals LP | $4,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-05-18 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2023 | |
| 2023-05-18 | AstraZeneca Pharmaceuticals LP | $9 | Travel and Lodging | In-kind items and services | IMFINZI Biological, Oncology | 2023 | |
| 2022-12-11 | AstraZeneca Pharmaceuticals LP | $2,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2022 | |
| 2022-11-30 | AstraZeneca Pharmaceuticals LP | $131 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-11-22 | AstraZeneca Pharmaceuticals LP | $2,220 | Consulting Fee | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2022 | |
| 2022-11-02 | AstraZeneca Pharmaceuticals LP | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2022 | |
| 2022-10-19 | Allergan, Inc. | $120 | Grant | In-kind items and services | NATRELLE SALINE-FILLED BREAST IMPLANTS Device, PLASTICS | 2022 | |
| 2022-08-18 | AstraZeneca Pharmaceuticals LP | $2,775 | Consulting Fee | Cash or cash equivalent | IMFINZI Biological, Oncology | 2022 | |
| 2022-04-12 | Daiichi Sankyo Inc. | $550 | Honoraria | Cash or cash equivalent | 2022 | ||
| 2022-02-24 | Gilead Sciences, Inc. | $2,800 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-01-12 | Daiichi Sankyo Inc. | $16 | Food and Beverage | In-kind items and services | ENHERTU Drug, ONCOLOGY | 2022 | |
| 2021-12-07 | GlaxoSmithKline, LLC. | $2,750 | Consulting Fee | Cash or cash equivalent | BLENREP Biological, ONCOLOGY | 2021 | |
| 2021-08-18 | Janssen Biotech, Inc. | $900 | Consulting Fee | Cash or cash equivalent | DARZALEX Biological, Oncology | 2021 | |
| 2021-06-01 | Gilead Sciences, Inc. | $11 | Education | In-kind items and services | 2021 | ||
| 2021-05-02 | AstraZeneca Pharmaceuticals LP | $1,665 | Consulting Fee | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2021 | |
| 2021-01-04 | AstraZeneca Pharmaceuticals LP | $1,942 | Consulting Fee | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2021 | |
| 2020-11-25 | Immunomedics, Inc. | $1,225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TRODELVY Drug, Oncology | 2020 | |
| 2020-11-23 | E.R. Squibb & Sons, L.L.C. | $19 | Education | Cash or cash equivalent | Revlimid Drug, Hematology | 2020 | |
| 2020-10-22 | Daiichi Sankyo Inc. | $2,220 | Consulting Fee | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-07-16 | E.R. Squibb & Sons, L.L.C. | $13 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2020 | |
| 2019-12-05 | Rigel Pharmaceuticals, Inc. | $36 | Travel and Lodging | In-kind items and services | Tavalisse Drug, Hematology | 2019 | |
| 2019-12-05 | Rigel Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | Tavalisse Drug, Hematology | 2019 | |
| 2019-11-20 | Rigel Pharmaceuticals, Inc. | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Tavalisse Drug, Hematology | 2019 | |
| 2019-11-09 | Rigel Pharmaceuticals, Inc. | $500 | Travel and Lodging | In-kind items and services | Tavalisse Drug, Hematology | 2019 | |
| 2019-11-09 | Rigel Pharmaceuticals, Inc. | $288 | Travel and Lodging | In-kind items and services | Tavalisse Drug, Hematology | 2019 | |
| 2019-11-09 | Rigel Pharmaceuticals, Inc. | $50 | Food and Beverage | In-kind items and services | Tavalisse Drug, Hematology | 2019 | |
| 2019-11-09 | Rigel Pharmaceuticals, Inc. | $35 | Food and Beverage | In-kind items and services | Tavalisse Drug, Hematology | 2019 | |
| 2019-06-19 | GENZYME CORPORATION | $2,019 | Consulting Fee | Cash or cash equivalent | JEVTANA Drug, ONCOLOGY | 2019 | |
| 2019-06-19 | GENZYME CORPORATION | $136 | Food and Beverage | In-kind items and services | JEVTANA Drug, ONCOLOGY | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Chaska, MN, county Carver County, MN, state Minnesota; placed by its city name.
| Measure | Place (city or town) Chaska, MN | County Carver County, MN | State Minnesota |
|---|---|---|---|
| Population B01003 | 28,706 | 110,041 | 5,739,445 |
| Population, 2020 census P1 | 27,810 | 106,922 | 5,706,494 |
| Median age B01002 | 37.5 | 39.0 | 38.8 |
| Under 18 B01001 | 26.0% | 25.2% | 22.9% |
| 65 and over B01001 | 13.4% | 14.5% | 17.3% |
| Households B11001 | 11,051 | 41,175 | 2,307,955 |
| Foreign born B05002 | 7.1% | 5.6% | 8.7% |
| Median household income B19013 | $110,956 | $125,946 | $89,062 |
| Median family income B19113 | $147,635 | $154,249 | $113,993 |
| Per capita income B19301 | $56,397 | $60,893 | $48,237 |
| Poverty rate B17001 | 5.8% | 4.4% | 9.3% |
| Unemployment rate B23025 | 3.2% | 3.1% | 4.1% |
| Civilian labor force B23025 | 16,877 | 62,717 | 3,119,042 |
| Mean commute (minutes) B08013 | 23.0 | 25.6 | 22.7 |
| Bachelor's degree or higher B15003 | 46.6% | 50.4% | 39.4% |
| Housing units B25001 | 11,104 | 42,270 | 2,545,030 |
| Owner-occupied B25003 | 67.6% | 81.5% | 72.2% |
| Renters B25003 | 32.4% | 18.5% | 27.8% |
| Median home value B25077 | $404,700 | $453,600 | $329,300 |
| Median gross rent B25064 | $1,553 | $1,514 | $1,280 |
| White, not Hispanic B03002 | 78.5% | 85.5% | 75.9% |
| Black B03002 | 3.2% | 1.6% | 6.9% |
| Hispanic or Latino B03002 | 9.8% | 5.1% | 6.4% |
| Asian B03002 | 3.8% | 3.3% | 5.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.7% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Chaska, MN.
Comments